Ionis Pharmaceuticals Drops Another After Phase 3 Setback
Ionis Pharmaceuticals dropped again after a Phase 3 failure in transthyretin amyloid cardiomyopathy, triggering a bro...
Find out which option tends to yield steadier income—index funds or bonds—and how to blend them for reliability and growth.
24,934 articlesIonis Pharmaceuticals dropped again after a Phase 3 failure in transthyretin amyloid cardiomyopathy, triggering a bro...
CleanSpark stock surged after disclosing a $6.6 billion, 20-year data center lease in Georgia, underscoring a shift f...
The horizon ahead is dotted with questions about SoFi and its next investor update. This guide lays out a practical f...
Apple is taking a guarded AI route, leaning on partnerships and modest capex. The strategy could alter AI investing d...
Rocket Lab is shaping the small-launch landscape, and the company’s 2025 earnings story matters for investors. This g...
This deep dive breaks down alto 2025 earnings, focusing on Q4 results, revenue growth, and what management signals fo...
Netflix has shown strong momentum, but a stock price path hinges on more than business strength. This article breaks ...
Ford is plotting a bold move with ford's next generation electric—a scalable, low-cost EV platform designed to suppor...
Investors are weighing CoreWeave against top AI stocks. This guide explains the risks, introduces three solid alterna...
Robotaxi chatter tends to focus on all-or-nothing automation. This article explains why Uber's hybrid network could b...
The stock market live march update shows the S&P 500 slipping as a Trump deadline extension adds uncertainty. Traders...
Hut 8 is pivoting to AI data center infrastructure, prompting a Canaccord upgrade that nearly doubles the firm’s pric...